Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiency

Background: Common variable immunodeficiency (CVID) is the most common symptomatic syndrome among inborn errors of immunity. Although several aspects of CVID immunopathology have been elucidated, predictive factors for mortality are incompletely defined. A genetic cause can be identified only in app...

Full description

Saved in:
Bibliographic Details
Main Authors: Adrian Kahn, MD, PhD, Gabriela Luque, BSc, Eduardo Cuestas, MD, PhD, Ana Basquiera, MD, PhD, Brenda Ricchi, BSc, Klaus Schmitz-Abe, PhD, Louis-Marie Charbonnier, MD, Mehdi Benamar, PhD, Ruben Dario Motrich, PhD, Talal A. Chatila, MD, PhD, Virginia E. Rivero, PhD
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829324001073
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846169372251389952
author Adrian Kahn, MD, PhD
Gabriela Luque, BSc
Eduardo Cuestas, MD, PhD
Ana Basquiera, MD, PhD
Brenda Ricchi, BSc
Klaus Schmitz-Abe, PhD
Louis-Marie Charbonnier, MD
Mehdi Benamar, PhD
Ruben Dario Motrich, PhD
Talal A. Chatila, MD, PhD
Virginia E. Rivero, PhD
author_facet Adrian Kahn, MD, PhD
Gabriela Luque, BSc
Eduardo Cuestas, MD, PhD
Ana Basquiera, MD, PhD
Brenda Ricchi, BSc
Klaus Schmitz-Abe, PhD
Louis-Marie Charbonnier, MD
Mehdi Benamar, PhD
Ruben Dario Motrich, PhD
Talal A. Chatila, MD, PhD
Virginia E. Rivero, PhD
author_sort Adrian Kahn, MD, PhD
collection DOAJ
description Background: Common variable immunodeficiency (CVID) is the most common symptomatic syndrome among inborn errors of immunity. Although several aspects of CVID immunopathology have been elucidated, predictive factors for mortality are incompletely defined. A genetic cause can be identified only in approximately 30% of patients. Objective: We sought to develop a mortality predictive score on the basis of the immunophenotypes and genotypes of patients with CVID. Methods: Twenty-one patients diagnosed with CVID in Córdoba, Argentina, were analyzed for clinical and laboratory data. Immunophenotyping was done by flow cytometry. CVID-associated mutations were identified by whole-exome sequencing. Results: Alive (15) and deceased (6) patients were compared. Univariate analysis showed significant differences in CD4+ T cells (P = .002), natural killer (NK) cells (P = .001), and memory switched B cells (P = .001) between groups. Logistic regression analysis showed a negative correlation between CD4+, NK, and memory switched B-cell counts and probability of survival over a 10-year period (CD4+ T cells: odds ratio [OR], 1.01; 95% CI, 1.001-1.020; NK cells: OR, 1.07; 95% CI, 1.02-1.17; and memory switched B cells: OR, 26.23; 95% CI, 2.06-2651.96). Receiver-operating characteristic curve analysis identified a survival cutoff point for each parameter (CD4+ T cells: 546 cells/mL; AUC, 0.87; sensitivity, 60%; specificity, 100%; memory switched B cells: 0.84 cells/mL; AUC, 0.92; sensitivity, 100%; specificity, 85%; and NK cells: 45 cells/mL; AUC, 0.92; sensitivity, 83%; specificity, 100%). Genetic analysis on 14 (9 female and 5 male) patients from the cohort revealed mutations associated with inborn errors of immunity in 6 patients. Conclusions: A score to predict mortality is proposed on the basis of CD4+ T, NK, and memory switched B-cell counts in patients with CVID.
format Article
id doaj-art-da6e33b9adc54019b9431935a91780cc
institution Kabale University
issn 2772-8293
language English
publishDate 2024-11-01
publisher Elsevier
record_format Article
series Journal of Allergy and Clinical Immunology: Global
spelling doaj-art-da6e33b9adc54019b9431935a91780cc2024-11-13T04:30:44ZengElsevierJournal of Allergy and Clinical Immunology: Global2772-82932024-11-0134100311Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiencyAdrian Kahn, MD, PhD0Gabriela Luque, BSc1Eduardo Cuestas, MD, PhD2Ana Basquiera, MD, PhD3Brenda Ricchi, BSc4Klaus Schmitz-Abe, PhD5Louis-Marie Charbonnier, MD6Mehdi Benamar, PhD7Ruben Dario Motrich, PhD8Talal A. Chatila, MD, PhD9Virginia E. Rivero, PhD10Servicio de Alergia e Inmunología Clínica, Hospital Privado Universitario de Córdoba, Córdoba, Argentina; Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina; FOCIS Center of Excellence Centro de Inmunologia Clinica de Cordoba (CICC), Córdoba, Argentina; Corresponding author: Adrian Kahn, MD, PhD, Av Naciones Unidas 346, Parque Velez Sarsfielf, Cordoba 5010, Argentina. Or: Virginia E. Rivero, PhD, Haya de la Torre y Medina Allende, Ciudad Universitaria, Cordoba 5000, Argentina.Servicio de Oncohematologia, Hospital Privado Universitario de Córdoba, Córdoba, ArgentinaInstituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina; Servicio de Pediatria, Hospital Privado Universitario de Córdoba, Córdoba, ArgentinaInstituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina; Servicio de Oncohematologia, Hospital Privado Universitario de Córdoba, Córdoba, ArgentinaServicio de Oncohematologia, Hospital Privado Universitario de Córdoba, Córdoba, ArgentinaDivision of Immunology, Boston Children’s Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass; Manton Center for Orphan Disease Research, Boston Children’s Hospital, Boston, Mass; Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine and Holtz Children’s Hospital, Jackson Health System, Miami, FlaDivision of Immunology, Boston Children’s Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, MassDivision of Immunology, Boston Children’s Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, MassFOCIS Center of Excellence Centro de Inmunologia Clinica de Cordoba (CICC), Córdoba, Argentina; Centro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Córdoba, Argentina; Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, ArgentinaDivision of Immunology, Boston Children’s Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, MassFOCIS Center of Excellence Centro de Inmunologia Clinica de Cordoba (CICC), Córdoba, Argentina; Centro de Investigaciones en Bioquímica Clínica e Inmunología, CIBICI-CONICET, Córdoba, Argentina; Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina; Corresponding author: Adrian Kahn, MD, PhD, Av Naciones Unidas 346, Parque Velez Sarsfielf, Cordoba 5010, Argentina. Or: Virginia E. Rivero, PhD, Haya de la Torre y Medina Allende, Ciudad Universitaria, Cordoba 5000, Argentina.Background: Common variable immunodeficiency (CVID) is the most common symptomatic syndrome among inborn errors of immunity. Although several aspects of CVID immunopathology have been elucidated, predictive factors for mortality are incompletely defined. A genetic cause can be identified only in approximately 30% of patients. Objective: We sought to develop a mortality predictive score on the basis of the immunophenotypes and genotypes of patients with CVID. Methods: Twenty-one patients diagnosed with CVID in Córdoba, Argentina, were analyzed for clinical and laboratory data. Immunophenotyping was done by flow cytometry. CVID-associated mutations were identified by whole-exome sequencing. Results: Alive (15) and deceased (6) patients were compared. Univariate analysis showed significant differences in CD4+ T cells (P = .002), natural killer (NK) cells (P = .001), and memory switched B cells (P = .001) between groups. Logistic regression analysis showed a negative correlation between CD4+, NK, and memory switched B-cell counts and probability of survival over a 10-year period (CD4+ T cells: odds ratio [OR], 1.01; 95% CI, 1.001-1.020; NK cells: OR, 1.07; 95% CI, 1.02-1.17; and memory switched B cells: OR, 26.23; 95% CI, 2.06-2651.96). Receiver-operating characteristic curve analysis identified a survival cutoff point for each parameter (CD4+ T cells: 546 cells/mL; AUC, 0.87; sensitivity, 60%; specificity, 100%; memory switched B cells: 0.84 cells/mL; AUC, 0.92; sensitivity, 100%; specificity, 85%; and NK cells: 45 cells/mL; AUC, 0.92; sensitivity, 83%; specificity, 100%). Genetic analysis on 14 (9 female and 5 male) patients from the cohort revealed mutations associated with inborn errors of immunity in 6 patients. Conclusions: A score to predict mortality is proposed on the basis of CD4+ T, NK, and memory switched B-cell counts in patients with CVID.http://www.sciencedirect.com/science/article/pii/S2772829324001073CVIDscoremortalityoutcomesWESB-cell subpopulations
spellingShingle Adrian Kahn, MD, PhD
Gabriela Luque, BSc
Eduardo Cuestas, MD, PhD
Ana Basquiera, MD, PhD
Brenda Ricchi, BSc
Klaus Schmitz-Abe, PhD
Louis-Marie Charbonnier, MD
Mehdi Benamar, PhD
Ruben Dario Motrich, PhD
Talal A. Chatila, MD, PhD
Virginia E. Rivero, PhD
Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiency
Journal of Allergy and Clinical Immunology: Global
CVID
score
mortality
outcomes
WES
B-cell subpopulations
title Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiency
title_full Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiency
title_fullStr Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiency
title_full_unstemmed Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiency
title_short Immunological biomarkers associated with survival in a cohort of Argentinian patients with common variable immunodeficiency
title_sort immunological biomarkers associated with survival in a cohort of argentinian patients with common variable immunodeficiency
topic CVID
score
mortality
outcomes
WES
B-cell subpopulations
url http://www.sciencedirect.com/science/article/pii/S2772829324001073
work_keys_str_mv AT adriankahnmdphd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT gabrielaluquebsc immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT eduardocuestasmdphd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT anabasquieramdphd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT brendaricchibsc immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT klausschmitzabephd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT louismariecharbonniermd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT mehdibenamarphd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT rubendariomotrichphd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT talalachatilamdphd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency
AT virginiaeriverophd immunologicalbiomarkersassociatedwithsurvivalinacohortofargentinianpatientswithcommonvariableimmunodeficiency